MS4A6A

Across TCGA pan-cancer cohorts, MS4A6A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MS4A6A data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MS4A6A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MS4A6A expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where MS4A6A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.276	0.510	<.001	40	view →
GBM	DFS	Median	All	0.275	0.444	.009	8	view →
HNSC	OS	Median	All	0.841	0.621	.003	8	view →
LSCC	OS	Quartile	III,IV	0.972	0.641	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MS4A6A–PDAC (OS)

Open the PDAC breakdown →